• Auscrete owns proprietary technology in hybrid insulated lightweight concrete building products manufacturing
• Company’s focus is on the “Green” movement
• Auscrete is finalizing plans to establish a 75 percent company-owned production plant in Ontario, Canada, with a Canadian Investment Group

A building materials manufacturing company based in Washington, Auscrete Corp. (OTC: ASCK) is at the vanguard of the “Green” movement. The company’s mission is to make affordable, technology-driven and eco-friendly housing available to those who were never before given the opportunity to realize the American Dream.

Auscrete Canada Ltd., as the new company is known, was formed to finance the construction and implementation of a manufacturing facility for its building products. The company will use Auscrete’s proprietary technology in hybrid insulated lightweight concrete building products, and it is leveraging this technology to provide a solution for those who want to buy their own solid, energy efficient, essentially fireproof Auscrete homes.

With its emphasis on the “Green” movement, the company is positioned to capitalize on the ever-growing trend toward environmentally friendly and non-toxic products. ConstructConnect noted that green and sustainable construction has developed from a marginal movement to realize mainstream status (http://ibn.fm/hRcM3). It further said that, “Reducing energy usage and water usage are the top environmental issues driving green construction.”

The technology in Auscrete’s products has been shown to considerably reduce energy usage for heating and cooling while only costing around $100 per square foot to construct. The technology has accomplished this via the use of high level insulation, consequently lessening energy pollution.

Now, Auscrete is in the final stages of plans to set up a 75 percent company-owned production plant with a Canadian investment group. The Canadian group will take a 25 percent interest in the facility, which is to be located near London, Ontario. Spiro Sapounas of London, Ontario, leads the Canadian investment group.

This facility can address the need for affordable housing, both across Canada and in the northeastern United States, where the closest U.S. plant is in the Pacific Northwest. The project also has numerous aspects that may make it suitable for government financial involvement and assistance. Sapounas has met with state and federal governments regarding the facility’s eligibility in this regard.

In a recent news release, Auscrete spokesman Lee Odom said, “Based on the conservative model of projections for this facility with a 12-month production level of 300 homes, Annual Revenue of $45 million is expected. Also, those conservative estimates are based on 1,500 sq. ft. homes whereas most are above that average, so in reality, that number could be higher depending on the demographic region.”

The Ontario facility will be similar to Auscrete’s flagship head office facility in Goldendale, Washington. This plant, with projected manufacturing of building products for 300 houses annually, will employ more than 150 people.

GenieBelt noted that in many countries there exists a dearth of housing while population growth is rising, and poverty is widespread (http://ibn.fm/sqNF5). It stated, “One of the solutions to these problems can be sustainable housing, but whether these homes can be made affordable enough for the average Joe to own or rent is another question.”

As a builder of “Green” energy efficient housing and commercial structures made from its lightweight hybrid concrete/insulation wall and roof panels, Auscrete is now taking its expertise into new areas to fulfill affordable housing needs. The Canadian facility project furthers the company’s vision in this regard.

For more information, visit the company’s website at www.AuscreteHomes.com

• PRO 140 single agent therapy is the first successful single agent therapy in the history of HIV for a sub-population of HIV
• Response rate for the company’s innovative PRO 140 nearly doubled after dosage increase
• About 70 percent of phase 3 trial participants treated with higher doses have achieved viral load suppression
• The monotherapy would allow patients to self-administer one dose per week of PRO 140 at home

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) has announced significant developmental progress for its PRO 140 monotherapy for human immunodeficiency virus (HIV) after noticing improved response rates at higher doses of the treatment during phase 3 trials (http://ibn.fm/yuYub). The company has received clearance from the independent Institutional Review Board (IRB) to increase the weekly dose of PRO 140 from 525 mg to 700 mg, according to a company press release.

The dosage increase will apply to all newly enrolled patients but also to current trial participants who failed to maintain suppressed HIV viral load on a lower dose. Approximately 70 percent of trial participants who started PRO 140 at 525 mg and have been undergoing treatment between one and nine months are achieving HIV viral load suppression, according to CytoDyn President and CEO Nader Pourhassan, Ph.D. Increasing the dosage further, to 700 mg per week, is expected to have even better results. “This IRB decision is exciting for patients, our Company and our shareholders, given the potential for a higher patient response rate with PRO 140 as a single agent at the 700 mg dose level,” Pourhassan explained in a news release.

The CytoDyn CEO added that, as the phase 3 trial progresses, exact response rates for participants taking 525 mg per week could vary. So far, there has been a clear distinction between response rates at 525 mg and the lower 350 mg per week. We believe increasing the dosage to 700 mg has the potential to achieve an even higher response rate.

PRO 140 is one of the company’s leading monoclonal antibodies being developed for HIV infection and certain other immunological disorders, including cancer. PRO 140 works by blocking the HIV co-receptor CCR5 on T-cells that block viral entry. Phase 1 and 2 clinical trial results have indicated that PRO 140 has no negative effect on normal immune functions mediated by CCR5, while being able to significantly reduce viral loads in patients. The phase 3 trial aims to assess the safety, tolerability and efficacy of PRO 140 as a long-acting single-agent maintenance therapy for HIV chronic suppression. If successful, this monotherapy would allow patients to safely self-administer once per week at home, without needing to take daily pills any longer.

Participants in the phase 3 clinical trial were screened for CCR5-tropic HIV infection and had a suppressed viral load under an existing highly active antiretroviral therapy when they started the study. At the beginning, participants were administered weekly PRO 140 doses of 350 mg, with roughly 40 percent being able to maintain suppressed viral load at that dosage. After treating the first 150 patients, CytoDyn increased the weekly dose to 525 mg, and a majority of the patients who did not respond to the lower dose were able to successfully re-suppress their viral loads when switching to the increased dosage.

“Patients who achieve suppressed HIV viral load after 10 weeks tend to maintain suppressed viral load.  Interestingly, some patients in our Phase 2b extension study are now achieving suppressed HIV viral load for nearly four years with PRO 140 as a single agent,” Pourhassan added.

Additionally, all phase 3 trial participants that did not respond to PRO 140 were able to safely achieve suppressed HIV viral load when returning to their previous retroviral therapy. “This is a major achievement as patients continue to have options for maintaining HIV viral load suppression,” said one of the main investigators of the phase 2 monotherapy trial, Jacob Lalezari, M.D., director of Quest Clinical Research and assistant clinical professor of medicine at UCSF/Mount Zion Hospital.

Specializing in humanized monoclonal antibodies and their clinical development, CytoDyn’s groundbreaking advancements in treatments for HIV and other immune deficiency viruses are providing ample opportunities for investors. The company intends to develop PRO 140 both as monotherapy and as part of a combination therapy, but also to pursue non-HIV, inflammatory indications where CCR5 and its ligand CCL5 are involved.

For more information, visit the company’s website at www.Cytodyn.com

• U.S. Securities and Exchange Commission continues to review cryptocurrency ETF applications
• Application by Chicago Board Options Exchange generating buzz among investors
• VRCP’s ATM platform helping to strengthen bitcoin’s legitimacy through “spendability” and technological practicality

As the U.S. Securities and Exchange Commission weighs several applications seeking to establish an exchange-traded investment fund (ETF) for the bitcoin cryptocurrency, Virtual Crypto Technologies Inc. (OTCQB: VRCP) is applauding the signs that regulatory sentiment in the United States appears to be shifting in favor of cryptocurrencies, paving the way for anticipated mass adoption of bitcoin (Crypto: BTC) and other cryptocurrencies.

Virtual Crypto Technologies is a company dedicated to making the financial flexibility of cryptocurrencies more accessible to the public through software- and hardware-based payment solutions that elevate the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and/or mobile devices.

As such, Virtual Crypto considers its experience in enabling the rapid exchange of cryptocurrency and traditional fiat currency to be an advantage in positioning the company to capitalize on the ETF debate as expectations rise that the SEC will approve a bitcoin ETF this year, perhaps as early as August.

“The fact that a regulatory body as important as the SEC is seriously considering a Bitcoin ETF, as well as notable development in the cryptocurrency ecosystem such as MasterCard’s intention to allow blockchain currencies to be transacted on traditional payment channels, validates our vision that cryptocurrencies are here to stay and that an era of virtual coins as a payment method for the masses is just around the corner,” Virtual Crypto CEO Alon Dayan stated in a recent news release (http://ibn.fm/Wi9Rl).

Researchers at Imperial College London reported that digital currencies are overcoming doubts about their trustworthiness and usefulness (http://ibn.fm/lzOai), fueling predictions that bitcoin and other cryptocurrencies will become mainstream forms of payment for goods and services within the next decade.

In late July, the SEC issued its latest denial of a bitcoin ETF, finding that the proposed product wasn’t safe enough for investors (http://ibn.fm/ygruE). However, the agency continues to review numerous other bitcoin ETF proposals, such as a fund advanced by the Chicago Board Options Exchange (CBOE) (http://ibn.fm/dlXmh) that has gained significant interest among investors (http://ibn.fm/wlklS). Industry publication Bitcoinist reported on August 2 that one of the four currently active SEC commissioners is continuing to promote cryptocurrency ETFs as an Exchange Act-consistent device for increasing investor opportunities and sustaining important innovation in the nation’s capital markets (http://ibn.fm/0CcO1).

A recent audio press release highlighting Virtual Crypto Technologies’ position notes that the acid test for determining the legitimacy of blockchain-based currencies such as bitcoin is increasingly being defined by their “spendability” and technological practicality (http://ibn.fm/PNOx9).

Virtual Crypto’s technology has helped establish that legitimacy for bitcoin through its bi-directional NetoBit ATM platform, which enables consumers to withdraw cash from their bitcoin accounts and transfer funds to the accounts without the need for banking institution hurdles and their fees. While a variety of altcoin ATMs are proliferating across North America, with more than 73 percent of them located on the continent (http://ibn.fm/WJNo7), the vast majority of those ATMS only provide “one-way” purchasing of crypto funds.

The uniqueness of the platform is visible in its currency exchange transaction validation (CETV) protocols that speed up the completion of cash or fintech transfers through proprietary transaction confirmation that establishes the probability of a transaction being confirmed, even while the verification by multiple miners is taking place. It is currently accessible to the consumer through Android and iOS mobile apps (http://ibn.fm/wGsGI). The products, working together, allow Virtual Crypto to take economic freedom to the next level.

For more information, visit the company’s website at www.Virtual-Crypto.com

• PHVAF inks agreement with Acosta’s National Specialty Sales division to sell to 2,400 retailers across U.S., will later have access to 25,000 more supermarkets, such as Wal-Mart and Target
• Jim Bailey, PHVAF CEO and president, terms crossover distribution into mainstream national retailers a “significant milestone” for the CBD industry; market channel is valued at $4.1 billion
• OKI line to consist of CBD-infused beverages, such as iced tea and flavored infused waters, plus tinctures and capsules; it will be available to consumers in 3Q2018

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) will launch its OKI brand of premium CBD products to consumers in 3Q2018 after gaining exposure to some 2,400 mainstream retail outlets across the U.S. when it signed an exclusive national agreement with National Specialty Sales (NSS), an Acosta company. Those stores include Whole Foods Market, Sprouts Farmers Market and National Coop Grocers. The total market channel is valued at greater than $4.1 billion in retail sales, PHVAF announced (http://ibn.fm/Vt0YR).

A video presentation of the announcement is available on the company’s YouTube channel (http://ibn.fm/BrCfg).

The partnership also provides the opportunity to access an additional 25,000 national grocery supermarkets such as Wal-Mart, Target, Kroger and others in Acosta’s national sales network. PHVAF and Acosta are working together to develop in-store merchandising, pricing, sampling and other promotions in order to ensure the success of the OKI line. They are also seeking to maintain direct client relationships and in-store inventory levels.

PHVAF is a Vancouver, Canada, based manufacturer of CBD derived from hemp infused into functional foods, beverages and health products. OKI is the company’s newest line of CBD-infused flavored iced tea, flavor-infused waters and tinctures and capsules. PHVAF also offers the Vida line of premium hemp-infused products, which includes Hemp Oil Extract and Hemp Oil Capsules. The company was recently uplisted to the OTCQX Best Market (http://ibn.fm/dspRQ).

Acosta is a premier food and beverage brokerage agency with more than 100 offices across the U.S. and Canada. Its NSS division has more than 475 sales associates managing the 2,400 retail natural specialty grocery stores.

In a news release, Jim Bailey, CEO and president of PHVAF, said, “This exclusive national agreement with Acosta and NSS is a major growth opportunity for Phivida, and a significant milestone for our industry overall… We are thrilled that Acosta/NSS have selected Phivida as their exclusive CBD beverage company, establishing Phivida’s new OKI label as the first CBD brand to officially cross-over into national mainstream distribution across the USA.”

The launch will begin within the natural/specialty channel, but it is expected that conventional retailers, such as major national grocery stores, will soon follow, according to Doug Campbell, PHVAF’s chief commercial officer.

John Caruso, National SVP-Business Development Strategic Channels at Acosta, added, “CBD-hemp oil infused functional beverages and oil supplements are one of the most exciting new product lines we are bringing to the NSS division… We believe that the team, the OKI brand, and the product quality and marketing strategy make Phivida a cut above the competition and the premier offering within this category. We are excited to bring the OKI products to health and wellness-minded consumers.”

For more information, visit the company’s website at www.Phivida.com

• Earth Science Tech to add three full-spectrum CBD chocolate offerings to product line
• Testing to begin on CBD-based patent products
• Earth Science Tech products will be available to 90,000 retail outlets throughout U.S.

On the heels of a major decision by the U.S. Food and Drug Administration (FDA) to approve Epidiolex, a drug derived from pure cannabidiol (CBD), to treat seizures associated with certain forms of severe epilepsy, Earth Science Tech, Inc. (OTC: ETST) is repositioning its line of full-spectrum CBD offerings.

Included in this move is the announcement that the company, along with joint venture partner Karmavore Superfoods, will be adding three full-spectrum cannabinoid chocolate products to its CBD line. The options — chocolate-covered mangoes, chocolate coconut peppermint cups and chocolate caramelized quinoa crunch — will contain Earth Science Tech’s high-grade cannabinoid oil and raw arriba nacional cacao, as well as other natural organic superfood ingredients. The chocolates are slated to be available during the third quarter of 2018.

In addition, Earth Science is scheduled to start testing on three new CBD-based patent formulas beginning in late 2018 and extending into 2019. In vitro testing on its first batch of formulas will be aimed at demonstrating the superior antioxidant properties and anti-proliferative effects on breast cancer cells. These compelling products are designed to stop inflammation, maintain quality of life and help prevent cancer and other degenerative diseases.

With these highly anticipated new products on the horizon, Earth Science is also focusing on making its products more available to consumers. The company recently signed agreements with AATAC to offer Earth Science’s CBD products to AATAC’s approximately 90,000 retail outlets throughout the United States. Based on growing consumer interest in CBD and positive response to the announcement, AATAC anticipates a high volume of preorders.

“Our association with AATAC, which is an advisory board that focuses on convenience stores, will give us the opportunity to open up and be available to a market that includes every sector of the population,” Jill Buzan, chief sales officer of ETST, stated in the news release. “This could lead to huge exponential growth for ETST’s sales in the next few months.”

This focus on CBD products is designed to solidify Earth Science’s position as a leader in a burgeoning CDB product markets. In the last three years, the hemp-derived CBD market has grown from $90 million to $190 million, and The Hemp Business Journal projects $2.1 billion in total CBD sales by 2020 (http://ibn.fm/ItwyP). This tremendous increase comes as a result of a growing recognition of CBD’s natural health and wellness properties, increased public acceptance and use of the ingredient and the wider accessibility — both online and in brick-and-mortar retail shops — of CBD products.

In addition to manufacturing, marketing and distributing cannabinoid products to the nutraceutical and pharmaceutical markets, Earth Science conducts R&D for low-cost, non-invasive medical devices.

For more information, visit the company’s website at www.EarthScienceTech.com

• 80 percent of the company’s total revenue anticipated from the licensing of DehydraTECH™
• Nuke Enterprises renewed its license, sending a strong vote of confidence in the technology
• Enabled GP Holdings to create a high-performing cannabis-infused beverage
• Biolog Inc. is developing products which will allow processors and consumers to turn almost any food or beverage into a cannabis edible
• Beginning production of a line of cannabis-infused alcohol-free beverages through a new licensing agreement

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, utilizes its unique patented DehydraTECH™ delivery technology to enhance the products of its clients. This patented delivery mechanism improves the bioabsorption and bioavailability of ingestible substances while also improving taste and smell. For companies entering into or already established in the cannabis industry, this is good news. The bitterness of cannabis when creating consumable products can now be reduced and even eliminated.

Lexaria has licensed DehydraTECH™ to a number of companies that market hemp-based, CBD-infused products. As the only company in the world awarded a patent for the improved delivery of all cannabinoids, Lexaria is strategically positioned to enable and partner with companies to improve high-quality products. Chris Bunka, CEO of LXRP, has indicated that 80 percent or more of the company’s total revenue will come from these licensing deals (http://ibn.fm/4VRLX).

A strong vote of confidence came from Nuka Enterprises. After using DehydraTECH™ for nearly two years, Nuka renewed its license with Lexaria. Nuka makes 1906 brand cannabis chocolates. Under the new 10-year semi-exclusive agreement, Nuka will utilize the technology in its U.S.-based products and plans to expand its products and brand to Canada (http://ibn.fm/eGhTA).

This same delivery technology enabled GP Holdings LLC to develop a high performing cannabis beverage with the complete clarity and transparency of sparkling beverages and nearly zero unwanted odors or flavors. GP acquired rights to DehydraTECH™ in a five-year semi-exclusive licensing agreement for beverage applications in California. GP is also working to develop topical skin products with this innovative tech.

Biolog, Inc. entered into an agreement back in February with Lexaria to utilize DehydraTECH™ in a unique line of manufactured dissolvable infusion products. These products will allow processors and consumers to turn almost any food or beverage into a cannabis edible (http://ibn.fm/ImeIs).

The most recent announcement comes from Lexaria and Hill Street Beverage Company Inc. They have signed a definitive agreement to license DehydraTECH™ in the production of a line of cannabis-infused alcohol-free beverages (http://ibn.fm/QAG8K). Hill Street plans to use DehydraTECH™ to create the same award-winning tastes it is known for while providing the consumer with the recreational experience of cannabis, void of any bitter taste. The alcohol-free red and white wines have already undergone lab testing by Lexaria and show virtually zero cannabis taste or odor with the use of DehydraTECH™.

In a news release, Hill Street CEO Terry Donnelly stated, “Our goal is to provide traditional beer and wine drinkers with great tasting products that use cannabis to mimic the onset and duration of effect that has historically come from alcohol, but without alcohol’s toxicity and added calories. While the early versions of our wines infused with Lexaria’s process have shown great promise, we are extremely excited about the progress Lexaria continues to make with their infusion technologies. Lexaria has already demonstrated its importance to our model as a key strategic partner in our business, and this agreement secures our future together. As Hill Street’s progress into producing the world’s finest alcohol-free and cannabis-infused beverages continues, Lexaria has demonstrated that they will continue to innovate and improve on their process. This will help to ensure Hill Street is always at the forefront of producing world-class wine, beer and other adult format beverages.”

Lexaria is expected to sign 6-12 more licensing agreements in 2018 through its four wholly owned subsidiaries serving the nicotine, hemp, pharmaceutical and cannabis industries.

For more information, visit the company’s website at www.LexariaBioscience.com

• Warren Wang, CEO of CIIX, says in MoneyTV interview that he believes CIIX will enjoy ‘good times’ in 2019 and 2020 as its program initiatives perform well
• He remains bullish on bitcoin pricing due to the fixed supply of 21 million coins and the potential demand from the far larger 1.4 billion-person population of China
• CIIX offers a suite of cryptocurrency services, including education, mining for coins and media; it offers its Chinese-speaking audience podcasts and a daily broadcast from the NYSE

ChineseInvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang recently predicted that CIIX would perform well and provide ‘good times’ for its shareholders in 2019 and 2020 as its programs develop. They include a comprehensive series of bitcoin services, such as the planned creation of an international bitcoin ATM network, and its core business of subscriptions and media relations.

In an interview on MoneyTV with host Donald Baillargeon, Wang said that he is confident in the strength of cryptocurrency due to fixed supply and a much greater potential for future demand (http://ibn.fm/iY1bc).

“There are only 21 million coins in the cryptocurrency market,” he said in the interview. “In China we have 1.4 billion people. Bitcoin is unique and has a limited supply. The doors and windows of supply are closed to everyone. Government cannot change it. A CEO cannot change it. That’s the beautiful part about cryptos.”

CIIX is all-in with programs for bitcoin and other virtual currencies. It offers a host of services including its own online site, NewCoins168.com, for real-time news. It also mines for cryptocurrencies with its own ASIC machines and AntMiners at a data center near Seattle (http://ibn.fm/7CrUW) and has established the Bitcoin Trading Academy for educational courses. In media, it has a daily broadcast from the NYSE, a cable TV program and a licensed podcast.

CIIX has an international Chinese-speaking audience. It also has core revenue from subscriptions and consulting. Its website notes that CIIX expects to issue its own ICO in the second half of 2018 or in 2019, issue currency and create a virtual investment ‘ecosystem’ for its Chinese viewers (http://ibn.fm/88Omb). Internationally, its future network of ATMs may expand into Canada from the U.S., and its bitcoin courses may be offered online to Asia.

“We have 70 employees worldwide in China and the U.S.,” Wang said during the MoneyTV interview. “In cryptocurrency we have banking, education, media and a trading platform ready to go. I think 2019 and 2020 will be good for us and our shareholders.”

For more information, visit the company’s website at www.ChineseInvestors.com

• Demand for lithium batteries in electric vehicles, energy storage devices and portable electronics continues to fuel lithium market forecasts
• QMC working with SGS Canada, Inc. to search out buried minerals through mobile metal ion (“MMI”) geochemical survey
• Company confident that additional exploration will expand property resource, historically reported to be in excess of 1.2 million tons grading at 1.5 percent Li2O

As investment research agencies continue to predict a boom market for lithium suppliers, QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) is moving forward with its plans to explore and develop a historical spodumene-bearing pegmatite resource located within Manitoba’s prolific Cat Lake-Winnipeg River rare-element pegmatite field.

Lithium Investing News joins a variety of market watchers in predicting that the excitement over junior miners’ efforts to fire up potential North American lithium extraction sites will be more than a flash in the pan as electric vehicles, energy storage systems and high-drain portable electronics call for low-heat, highly efficient batteries — the type that rely on limited supply elements such as lithium and cobalt. The investment news agency, citing research by the Freedonia Group, predicts that global demand for lithium metal will rise to 49,350 metric tons by next year, with a lithium carbonate equivalent (LCE) valuation of the global market projected to be $1.7 billion (http://ibn.fm/nz4VH).

This optimistic forecast coincides with QMC Quantum Minerals’ efforts to evaluate and revitalize its 100 percent-owned Irgon Lithium Mine Project. The property presents the prospect of a quick production ramp up once the company establishes market potential, particularly as part of the initial exploration and development 65 years ago, a 500-ton-per-day mill was erected onsite (which was subsequently removed from the property in 1963). A future production decision by QMC will be facilitated by the fact that significant infrastructure remains in place, including an underground complex of a three-compartment shaft, drifts and crosscuts that can be put to use in new exploration without having to start from scratch at ground level (http://ibn.fm/b0QK5).

Even though the company has historic underground development, the Irgon Dike’s lithium mineralization begins directly at the surface.  QMC Quantum Minerals is preparing to evaluate and potentially expand Irgon Dike strike extensions in addition to evaluating other spodumene-bearing pegmatite dikes that have been identified on the property by undertaking a mobile metal ion geochemical survey (mobile metal ions in this case will include elements such as lithium, cesium, niobium, tantalum, rubidium, beryllium, etc.).  These pathfinder elements have been released from underlying pegmatite mineralization and have traveled upward through the soil profile. In May, the company announced that SGS Canada, Inc. would provide expertise and assistance during the upcoming Irgon exploration and, on July 24, QMC announced that SGS will be assisting with the collection of the MMI geochemical samples and will provide analysis of MMI samples using its exclusive MMI technology (http://ibn.fm/LstIA).

Planning has begun for the MMI survey for buried mineralization over selected target areas at the Irgon Mine Property. According to both SGS and QMC, the MMI geochemical survey is a proven, advanced exploration technique that has been utilized elsewhere to identify buried mineral (pegmatite) deposits. The search will begin over mineralized areas above the Irgon Dike and work its way westward to identify any buried strike extensions of the Irgon Dike.

“Using careful soil sampling strategies, sophisticated chemical ligands and ultra-sensitive instrumentation, SGS is able to measure the concentration of these ions. … After interpretation, MMI data will indicate anomalous target areas on which to focus the subsequent drill program,” the news release states.

The historical exploration of the Irgon Dike more than six decades ago, long before the price of lithium reached its current fever levels, identified a resource estimate of over 1.2 million tons grading 1.51 percent Li2O over a strike length of 1,200 feet and to a depth of 700 feet.  This historical assessment is currently in the process of being upgraded to modern NI 43-101 reporting standards, with the reported historic resource expected to be potentially expanded both along strike and to depth.

QMC has stated that its re-evaluation of historical assessment reports filed on the property led it to identify an additional historical exploration target that encompasses “a large, untested lithium soil anomaly” more than 3,600 feet long and up to 1,150 feet wide across the southern part of the property. Exploration of this target area will be part of the upcoming MMI geochemical survey and is certainly a reason for the company’s enthusiasm.

For more information, visit the company’s website at www.QMCMinerals.com

• PreveCeutical’s ‘Nature Identical™’ efforts aim to create consistently reproducible versions of found-in-nature therapeutics
• Company has begun engineering redesign phase of select identified peptides derived from famed scorpion venom
• Preventative therapeutics market expected to generate $196.9 billion in revenues by 2024, demonstrating alternative health products’ potential

PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) efforts to develop a synthesized and consistently reproducible ‘Nature Identical™’ scorpion venom, popular as a pain reliever and cancer therapy, has taken a new step toward marketability as the company commences work on re-engineering venom peptide components to stabilize them.

The biotech company based in British Columbia, Canada, has established its purpose as delivering organic and nature-inspired products to patients dealing with certain select ailments, in the hope of providing the patients with affirmative treatment and, through immune system support, preventing the maladies from occurring in those not yet afflicted. PreveCeutical’s interests extend specifically to type 2 diabetes and obesity, mild traumatic brain injury, cancer and pervasive pain.

PreveCeutical’s work to provide the benefits of Caribbean Blue Scorpion venom to patients with mild head injuries and glioblastoma, a highly-aggressive form of brain cancer, has established the company as having a novel, natural approach to treating less-commonly researched ailments. Caribbean Blue Scorpion venom has long had some popular medicinal use among people in several nations, and PreveCeutical’s aim is to provide a consistent, high-quality source that doesn’t require someone to milk scorpions regularly in order to establish a supply.

The company completed its first phase of R&D on the project earlier this year, identifying eight scorpion peptides of such a size and nature that PreveCeutical could redesign and synthesize them for potential use in Nature Identical™ products. The company has now begun Phase 2 of the project, which involves doing the peptide redesign work with the goal of improving the peptides’ stability, so they can maintain their potency while being employed against the brain maladies, according to a news release issued on July 31, 2018 (http://ibn.fm/mADJx).

“The Company’s research team is using state-of-the-art computer technology for its in-silico modelling and docking studies, against known brain cancer targets (e.g. Matrix metalloproteinases) to determine the structural features and amino acid sequences critical to their binding,” the news release states.

Once PreveCeutical establishes a library of highly stable peptides, the company will begin the third phase of the program in which it begins screening the Nature Identical™ peptides in cell-based glioblastoma models.

One of the company’s primary goals is to establish a novel drug delivery method by producing a Sol-gel compound that can be administered nasally, creating a pathway for medicines such as cannabidiol contained within the Sol-gel to reach the brain directly from the nose without having to travel the digestive tract and risking its weeding-out barriers.

Crystal Equity Research noted that the company shifted its potential “into a higher gear with its development pipeline” after successfully raising C$6.5 million ($4.9 million) in June for useable capital (http://ibn.fm/pY5qK), as well as executing a five-for-one stock split that created the potential for greater liquidity. The research firm anticipates that preventative health care will continue to be a lucrative market, citing Grand View Research’s forecast for generating $196.9 billion in revenue by 2024 with a 15 percent CAGR.

“The recent capital raise provides some assurance that the R&D budget has sufficient support to reach milestones or at least produce relevant results,” Crystal Equity states.

For more information, visit the company’s website at www.PreveCeutical.com

• Operating in world’s two largest cannabis markets – California and Canada
• Cannabis concentrate extraction service agreement inked with Cannabis Strategic Venture subsidiary Pure Applied Sciences, Inc. to provide white label services of high quality, ultra-purified cannabis extracts
• Construction underway in California and Canada of large scale, purpose-built current cGMP designed greenhouses for cannabis cultivation and production
• Supply agreement with Canopy Growth Corporation to provide up to 90,000 kg of cannabis over two years beginning in early 2019

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF), a vertically integrated medical cannabis company headquartered in Vancouver, Canada, is committed to delivering safe, consistent, high-quality products and services through its wholly owned subsidiaries – Sunniva Medical Inc., CP Logistics LLC, Natural Health Service Ltd. and Full-Scale Distributors LLC.

In an executive summary of Sunniva’s market potential, Canaccord Genuity states, “Sunniva could become one of the larger compliant producers in California heading into 2019 where more than 85 percent of product is still not in compliance with current regulations.” The company’s strategy of placing a high degree of importance on designing its facilities with innovative technologies that allow for automation, low-cost cultivation and the ability to maximize control/monitoring of production inputs and environmental factors is a top value for investors looking at Sunniva, the report states (http://ibn.fm/dUISz).

Sunniva currently has two separate growing facilities under construction. The first facility is at its campus in Cathedral City, California, and the second is a 126-acre site at Okanagan Falls, British Columbia, Canada. Sunniva broke ground in early May 2018 on the Okanagan Falls Campus, while the Cathedral City Campus is further along in the construction process. Through subsidiary CP Logistics, the company is close to completing Phase 1 of a cGMP-compliant greenhouse facility in Cathedral City that will have an estimated annual output of 60,000 kg of dry cannabis at capacity. Sunniva expects operations at its California facility to begin in Q4 2018 (http://ibn.fm/GzxM9).

A previously reported take-or-pay supply agreement signed with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (http://ibn.fm/KAan1) ensures that Canopy will purchase approximately 45 percent of Sunniva’s annual production capacity, representing 45,000 kg of dried cannabis annually, starting in Q1 2019 or shortly thereafter. Canopy will also distribute Sunniva’s branded products. Canaccord Equity issued a positive statement on this agreement, noting, “We believe this take-or-pay agreement provides medium-term revenue certainty while partnering the company with one of the leading producers in Canada and allocating a sizable portion of the company’s planned capacity (~45%) to a dedicated supply channel right off the bat.”

Sunniva also recently signed a cannabis concentrate extraction services agreement between CP Logistics, LLC (“CPL”) and Pure Applied Sciences, Inc. (“PAS”), a wholly owned subsidiary of Cannabis Strategic Ventures, Inc. (OTC: NUGS). Under the agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for PAS under the Pure Organix™ brand name, which was recently acquired by Cannabis Strategic (http://ibn.fm/1jvcN).

In addition to its planned cultivation and production in California and Canada, Sunniva operates Canada’s largest network of cannabis clinics (providing guidance and education to medical patients) and is a private-label provider of vaporizers throughout several major U.S. states. Sunniva’s seed-to-sale structure supports the company’s strategy of sourcing potential acquisition targets to increase its level of vertical integration.

For more information, visit the company’s website at www.sunniva.com